[1] ALTIERI B, SECENER AK, SAI S, et al. Single-nucleus and spatial transcriptome reveal adrenal homeostasis in normal and tumoural adrenal glands. Clin Transl Med. 2024;14(8):e1798.
[2] HANEMAAIJER ES, MARGARITIS T, SANDERS K, et al. Single-cell atlas of developing murine adrenal gland reveals relation of Schwann cell precursor signature to neuroblastoma phenotype. Proc Natl Acad Sci U S A. 2021;118(5):e2022350118.
[3] DEL VALLE I, YOUNG MD, KILDISIUTE G, et al. An integrated single-cell analysis of human adrenal cortex development. JCI Insight. 2023;8(14):e168177.
[4] SUCHESTON ME, CANNON MS. Development of zonular patterns in the human adrenal gland. J Morphol. 1968;126(4):477-491.
[5] LUCHETTI S, LIERE P, PIANOS A, et al. Disease stage-dependent changes in brain levels and neuroprotective effects of neuroactive steroids in Parkinson’s disease. Neurobiol Dis. 2023;183:106169.
[6] SCHWARTZ AG. Dehydroepiandrosterone, Cancer, and Aging. Aging Dis. 2022; 13(2):423-432.
[7] LI L, WANG H, YAO Y, et al. The sex steroid precursor dehydroepiandrosterone prevents nonalcoholic steatohepatitis by activating the AMPK pathway mediated by GPR30. Redox Biol. 2021;48:102187.
[8] ZHANG S, ZHOU J, LI L, et al. Effect of dehydroepiandrosterone on atherosclerosis in postmenopausal women. Biosci Trends. 2022;15(6):353-364.
[9] WANG Y, GUO B, GUO Y, et al. A spatiotemporal steroidogenic regulatory network in human fetal adrenal glands and gonads. Front Endocrinol. 2022;13: 1036517.
[10] DAY R, DONG W, PANETTA R, et al. Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocrinology. 1995;136(11):5232-5235.
[11] AMPOFO E, NALBACH L, MENGER MD, et al. Regulatory mechanisms of somatostatin expression. Int J Mol Sci. 2020;21(11): 4170.
[12] 孙烁烁,韦晓,张少红,等.生长抑素治疗肥胖的分子机制研究进展[J].中国医药导报,2023,20(15):53-56.
[13] STENGEL A, TACHÉ YF. Activation of Brain Somatostatin Signaling Suppresses CRF Receptor-Mediated Stress Response. Front Neurosci. 2017;11:231.
[14] PATEL YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999; 20(3):157-198.
[15] AGUILERA G, HARWOOD JP, CATT KJ. Somatostatin modulates effects of angiotensin II in adrenal glomerulosa zone. Nature. 1981;292(5820):262-263.
[16] GÜNTHER T, TULIPANO G, DOURNAUD P, et al. International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev. 2018;70(4):763-835.
[17] 李卓凡,黄佳琪,孔炜.生长抑素受体2的功能与研究进展[J].生理科学进展,2022,53(5):385-389.
[18] ULANER GA, VANDERMOLEN LA, LI G, et al. Dotatate PET/CT and 225Ac-Dotatate Therapy for Somatostatin Receptor-expressing Metastatic Breast Cancer. Radiology. 2024;312(1):e233408.
[19] PELLEGRINO C, FAVALLI N, VOLTA L, et al. Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors. Oncoimmunology. 2024;13(1):2412371.
[20] THAKUR S, DALEY B, MILLO C, et al. 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer. Clin Cancer Res. 2021;27(5):1399-1409.
[21] HAN G, HWANG E, LIN F, et al. RYZ101 (Ac-225 DOTATATE) Opportunity beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small-Cell Lung Cancer. Mol Cancer Ther. 2023;22(12):1434-1443.
[22] HEO Y, YOON E, JEON YE, et al. Cryo-EM structure of the human somatostatin receptor 2 complex with its agonist somatostatin delineates the ligand-binding specificity. Elife. 2022;11:e76823.
[23] CAMPANA C, AMARÙ J, MILIOTO A, et al. Digital quantification of somatostatin receptor subtypes 2 and 5 in growth hormone-secreting pituitary tumors. Eur J Endocrinol. 2025;192(1):K6-K14.
[24] WU J, DING Y, WANG J, et al. Single-cell RNA sequencing in oral science: Current awareness and perspectives. Cell Prolif. 2022;55(10):e13287.
[25] LIANG DM, DU PF. scMUG: deep clustering analysis of single-cell RNA-seq data on multiple gene functional modules. Brief Bioinform. 2025;26(2):bbaf138.
[26] JOVIC D, LIANG X, ZENG H, et al. Single-cell RNA sequencing technologies and applications: A brief overview. Clin Transl Med. 2022;12(3):e694.
[27] CHEN Y, SONG J, RUAN Q, et al. Single-Cell Sequencing Methodologies: From Transcriptome to Multi-Dimensional Measurement. Small Methods. 2021;5(6): e2100111.
[28] FIGUEIREDO ML. Applications of single-cell RNA sequencing in rheumatoid arthritis. Front Immunol. 2024;15:1491318.
[29] CHENG C, CHEN W, JIN H, et al. A Review of Single-Cell RNA-Seq Annotation, Integration, and Cell-Cell Communication. Cells. 2023;12(15):1970.
[30] YANG M, MANDAL K, SÖDERGREN M, et al. Real-time detection of somatostatin release from single islets reveals hypersecretion in type 2 diabetes. Acta Physiol (Oxf). 2025;241(2):e14268.
[31] MILEWSKA-KRANC A, ĆWIKŁA JB, KOLASINSKA-ĆWIKŁA A. The Role of Receptor-Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors. Cancers (Basel). 2023;16(1):116.
[32] GERMANO A, RAPA I, DUREGON E, et al. Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma. Endocr Pathol. 2017;28(2):95-102.
[33] SPIGA F, ZHAO Z, LIGHTMAN SL. Prolonged treatment with the synthetic glucocorticoid methylprednisolone affects adrenal steroidogenic function and response to inflammatory stress in the rat. Brain Behav Immun. 2020;87:703-714.
[34] ZHANG X, SAARINEN AM, CAMPBELL LE, et al. Regulation of Lipolytic Response and Energy Balance by Melanocortin 2 Receptor Accessory Protein (MRAP) in Adipocytes. Diabetes. 2018;67(2):222-234.
[35] MILLER WL. MECHANISMS IN ENDOCRINOLOGY: Rare defects in adrenal steroidogenesis. Eur J Endocrinol. 2018;179(3):R125-R141.
[36] CAROCCIA B, VANDERRIELE PE, SECCIA TM, et al. Aldosterone and cortisol synthesis regulation by angiotensin-(1-7) and angiotensin-converting enzyme 2 in the human adrenal cortex. J Hypertens. 2021;39(8):1577-1585.
[37] ELLIOTT AD, USTIONE A, PISTON DW. Somatostatin and insulin mediate glucose-inhibited glucagon secretion in the pancreatic α-cell by lowering cAMP. Am J Physiol Endocrinol Metab. 2015;308(2):E130-E143.
[38] CHEN S, TENG X, ZHENG S. Molecular basis for the selective G protein signaling of somatostatin receptors. Nat Chem Biol. 2023;19(2):133-140.
[39] ROBERTSON MJ, MEYEROWITZ JG, PANOVA O, et al. Plasticity in ligand recognition at somatostatin receptors. Nat Struct Mol Biol. 2022;29(3):210-217.
[40] BEN-SHLOMO A, DENG N, DING E, et al. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. J Clin Invest. 2020;130(11): 5738-5755.
[41] EVANS JS, BEAUMONT J, BRAGA M, et al. Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy. Eur J Cancer. 2022;176: 110-120.
[42] JEPSEN SL, ALBRECHTSEN NJW, WINDELØV JA, et al. Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R-dependent manner. JCI Insight. 2021;6(4):e143228.
[43] HIRSCH A, HAHN D, KEMPNÁ P, et al. Role of AMP-activated protein kinase on steroid hormone biosynthesis in adrenal NCI-H295R cells. PLoS One. 2012;7(1): e30956.
[44] LEE JHZ, COLEMAN T, MCLEAN MA, et al. Selective α-Hydroxyketone Formation and Subsequent C-C Bond Cleavage by Cytochrome P450 Monooxygenase Enzymes. ACS Catal. 2024;14(11):8958-8971.
[45] XIAO F, SONG X, TIAN P, et al. Comparative Dynamics and Functional Mechanisms of the CYP17A1 Tunnels Regulated by Ligand Binding. J Chem Inf Model. 2020; 60(7):3632-3647.
[46] LIU Y, DENISOV IG, SLIGAR SG, et al. Substrate-Specific Allosteric Effects on the Enhancement of CYP17A1 Lyase Efficiency by Cytochrome b5. J Am Chem Soc. 2021;143(10):3729-3733.
[47] MAK PJ, DUGGAL R, DENISOV IG, et al. Human Cytochrome CYP17A1: The Structural Basis for Compromised Lyase Activity with 17-Hydroxyprogesterone. J Am Chem Soc. 2018;140(23):7324-7331.
[48] WRÓBEL TM, JØRGENSEN FS, PANDEY AV, et al. Non-steroidal CYP17A1 Inhibitors: Discovery and Assessment. J Med Chem. 2023;66(10):6542-6566.
[49] WRÓBEL TM, BARTUZI D, KACZOR AA. Secondary Binding Site of CYP17A1 in Enhanced Sampling Simulations. J Chem Inf Model. 2024;64(19):7679-7686.
[50] SINGH H, KUMAR R, MAZUMDER A, et al. Insights into Interactions of Human Cytochrome P450 17A1: A Review. Curr Drug Metab. 2022;23(3):172-187.
[51] PENHALE SH, PICCI G, OTT LR, et al. Impacts of adrenarcheal DHEA levels on spontaneous cortical activity during development. Dev Cogn Neurosci. 2022; 57:101153.
[52] VASANKARI T, KUJALA U, TAIMELA S, et al. Effects of a long acting somatostatin analog on pituitary, adrenal, and testicular function during rest and acute exercise: unexpected stimulation of testosterone secretion. J Clin Endocrinol Metab. 1995;80(11):3298-3303.
[53] WELLMAN K, FU R, BALDWIN A, et al. Transcriptomic Response Dynamics of Human Primary and Immortalized Adrenocortical Cells to Steroidogenic Stimuli. Cells. 2021;10(9):2376.
[54] MIERKE CT. Physical and biological advances in endothelial cell-based engineered co-culture model systems. Semin Cell Dev Biol. 2023;147:58-69.
[55] QI Y, YU L, TIAN F, et al. In vitro models to study human gut-microbiota interactions: Applications, advances, and limitations. Microbiol Res. 2023;270: 127336.
[56] DABKEVIČIŪTĖ G, PETRIKAITĖ V. Insights into 2D and 3D cell culture models for nanoparticle-based drug delivery to glioblastoma. Biochem Pharmacol. 2025;237:116931.
[57] PARENTE IA, CHIARA L, BERTONI S. Exploring the potential of human intestinal organoids: Applications, challenges, and future directions. Life Sci. 2024;352: 122875.
[58] JIN H, XUE Z, LIU J, et al. Advancing Organoid Engineering for Tissue Regeneration and Biofunctional Reconstruction. Biomater Res. 2024;28:0016.
[59] UPTON TJ, ZAVALA E, METHLIE P, et al. High-resolution daily profiles of tissue adrenal steroids by portable automated collection. Sci Transl Med. 2023;15(701): eadg8464.
[60] DEVASIA TP, DEWARAJA YK, FREY KA, et al. A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE. J Nucl Med. 2021;62(8):1118-1125.
[61] WU D, PLYKU D, KULKARNI K, et al. Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid Cancer. Clin Nucl Med. 2021;46(4):283-288.
[62] BROSCH-LENZ J, DELKER A, VÖLTER F, et al. Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy. J Nucl Med. 2023;64(5):767-774. |